INS and obesity disorder: For instance, the PPARG can regulate systemic insulin resistance, PPARG dysregulation will cause obesity, and HSP90AA1 can inhibit the reduction of adipogenesis through the in vivo pathway to trigger the anti-obesity effect [53,54].